GSK3B and type 2 diabetes mellitus: TDZD-8-mediated GSK-3β inhibition has been investigated in other pathological contexts, including type II diabetes mellitus [75] and various inflammatory diseases [76,77], suggesting that GSK-3β inhibition via TDZD-8 could be an effective therapeutic strategy for a broad range of pathologies.